Drug development relies on controlled environments to prevent products and processes from contamination during research and manufacture. To meet stringent product quality and patient safety standards, both sterile and non-sterile drug products require greater environmental control than ever before, especially in the wake of recent advances in the manufacture of complex biologics and advanced therapies.

As the third-largest global pharma manufacturing power[1] (by volume), alongside its significant contribution to the international market for generic medications, India is extremely well-placed to capitalise on this shift through investment in advanced cleanroom technology. This not only ensures that its output is compliant with GMP guidelines; developing cleanroom infrastructure will also deliver swift ROI and improvements to operational efficiency, reducing the likelihood of product recalls and the associated financial and reputational fallout. Particularly for Indian pharma manufacturers serving international markets, contamination control is a regulatory imperative, providing a vital argument for wider modernisation of manufacturing efforts.

Evolving Cleanroom Classification Standards and Regulatory Frameworks

International cleanroom classification standards provide the technical foundation for how these spaces are designed, while also establishing particle concentration limits for different cleanroom grades and defining testing methodologies to demonstrate compliance. Ranging from Class 1 to Class 9, the globally-recognised ISO 14644-1 standard[2] let pharma manufacturers make informed decisions about the facilities they use.

FDA guidance on sterile drug products establishes cleanroom grade requirements for different manufacturing activities, with its Grade A environments[3] required for critical operations including filling and stoppering, approximately equivalent to ISO Class 5 while in use. These grade specifications follow a risk-based approach, which applies the most stringent controls to operations with greatest contamination risk while allowing for more flexibility in supporting activities. This should still represent the minimum requirements, with the expectation on manufacturers to implement the appropriate contamination control strategies for their specific output and facilities.

In comparison, India follows Schedule M (Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products), whose cleanroom requirements are substantially aligned with international standards for the sake of exporting. India’s Central Drug Standards Control Organization (CDSCO) has strengthened its Schedule M requirements over time, intensifying inspection activities to reflect its imperative to maintain India's reputation as a global supplier of quality pharmaceutical products.

Managing Risk Through Contamination Control Strategies

Modern contamination control systems[4] rely on multiple interdependent elements running at once; these range from design features and physical systems such as ventilation, to training staff to follow strict protocols while in the cleanrooms themselves, as well as technological solutions like environmental monitoring systems[5] to ensure efficacy. To guarantee that these interlocking features work properly, manufacturers must conduct systematic risk assessment with full documentation and ongoing performance monitoring in order to clearly demonstrate that any contamination risks are being appropriately managed.

Facility design is the foundation of contamination control; these spaces require smooth, non-shedding surfaces made from the appropriate materials to make cleaning easier and minimise extraneous particle generation. The principles of pharma cleanroom design emphasise unidirectional workflows to prevent cross-contamination between different manufacturing activities, alongside ensuring that air flows from cleaner to less clean areas and keeping incompatible operations separate from one another to avoid compromising product quality. In terms of mechanical infrastructure, air handling systems are especially critical, as they filter air at appropriate velocities and air change rates to maintain designated particle concentrations and remove any contaminants generated during operations. High-efficiency particulate air (HEPA) filters, which can extract 99.97% of contaminant particles, are the standard technology for pharmaceutical-grade cleanrooms, with ultra-low penetration air (ULPA) filters being fitted for higher efficiency where necessary. Designing these systems must take multiple performance parameters[6] into account, such as air change rates, air velocity in areas of unidirectional flow and pressure changes between adjacent areas.

However, the most significant potential source of contamination is less difficult to keep under control: the introduction of employees who might be working in these cleanroom conditions. Human skin continuously sheds particles, increasing the likelihood of product quality being compromised if the issue is not adequately controlled. Beyond training employees in best practice, clothing procedures and behavioural controls should be put into place to reduce the chances of human error impacting output. Designing cleanroom facilities to incorporate airlocks where teams can gown and wash their hands in a suitable air pressure situation provides the best results, as well as the greatest likelihood of compliance.

A More Sustainable Approach to Contamination Control

Pharmaceutical cleanrooms typically consume 5–10 times more energy[7] per square metre than conventional commercial facilities, due to their continuous operation, extensive air filtration and the need to maintain precise temperature and humidity control at all times. The energy intensity of cleanroom operations creates both economic and environmental imperatives to adapt to pressures around meeting sustainability goals and staying within budgetary restrictions.

One of the most effective energy efficiency strategies[8] for contamination control facilities is the introduction of variable air volume (VAV) systems. These let cleanrooms operate at reduced airflow rates while they are unoccupied or in the midst of lower-activity operations; this requires sophisticated control systems to implement, but validation studies have demonstrated energy savings of up to 50% compared with constant air volume systems. Meanwhile, energy recovery systems like thermal wheels or plate heat exchangers are able to capture thermal energy from cleanroom exhaust air, transferring it to incoming supply air. This reduces the heating or cooling load required to condition fresh air to appropriate temperature specifications. For pharmaceutical manufacturing facilities located in India, this can be a game-changing way to achieve substantial energy savings over a payback period of between 2 and 5 years.

Integrating Environmental Monitoring Systems into Cleanroom Operations

Continuous environmental monitoring provides another essential component of pharmaceutical cleanroom operations, offering real-time visibility into air quality, surface cleanliness and microbial contamination. Rather than the manual sampling processes of the past, this approach allows for proactive intervention in the event of any deviations, while providing more comprehensive documentary evidence to demonstrate sustained compliance over time.

The two most common monitoring systems are also somewhat complementary. Non-viable particle monitoring makes use of laser-based particle counters to continually measure the concentration of airborne particles, letting pharmaceutical manufacturers detect contamination events immediately and investigate their root causes before product quality is compromised. Meanwhile, viable particle monitoring encompasses both airborne and surface sampling for microbial contamination, specifically assessing the risks of microbiological contamination. The placement of particle monitoring sample points across cleanrooms requires careful consideration of airflow patterns, contamination risk areas and operational activities in order to ensure that the data gives an accurate representation of performance to enable effective contamination control.

Cleanroom validation programmes use documented evidence to demonstrate consistent achievement and maintenance of specified environmental conditions throughout operational ranges. Validation protocols typically verify the correct installation of cleanroom systems, confirm their functional performance under different operating and manufacturing conditions.

As pharmaceutical cleanroom technology continues to evolve with increasing complexity and speed, it has created a surging demand for platforms that facilitate technology assessment, knowledge exchange and relationship development across the international pharma industry, bridging the gap between pharmaceutical manufacturers, equipment suppliers and technical service providers. CPHI & PMEC India, which takes place across two venues in Delhi from 23-26 November 2026, provides the ideal forum for organisations and individuals alike to make valuable connections to push contamination control forward.

The show will also feature a dedicated Cleanroom Technology zone where suppliers demonstrate their advanced contamination control systems, letting pharmaceutical professionals conduct comparative evaluations of competing systems and engage directly with technical experts. Seminars and case study presentations will take place across the show floor, providing insights into regulatory expectations, implementation best practice and case studies from previous major cleanroom projects. As cleanroom technology becomes an imperative for companies operating across India, this year’s show provides an unmissable opportunity for local and international suppliers and manufacturers alike to make global partnerships and futureproof their operations.